TN2011000362A1 - Pyridazinone compounds - Google Patents

Pyridazinone compounds

Info

Publication number: TN2011000362A1
Authority: TN; Tunisia
Prior art keywords: ring; substituent; substituted; compound; pyridazinone compounds
Prior art date: 2009-02-05

Application number

TN2011000362A

Other languages

English (en)

Inventor

Takahiko Taniguchi

Akira Kawada

Mitsuyo Kondo

John F Quinn

Jun Kunitomo

Masato Yoshikawa

Makoto Fushimi

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-05

Filing date

2011-07-22

Publication date

2013-03-27

2011-07-22 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2013-03-27 Publication of TN2011000362A1 publication Critical patent/TN2011000362A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Obesity (AREA)
Hematology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

TN2011000362A 2009-02-05 2011-07-22 Pyridazinone compounds TN2011000362A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20220709P	2009-02-05	2009-02-05
US21392709P	2009-07-30	2009-07-30
PCT/US2010/000307 WO2010090737A1 (fr)	2009-02-05	2010-02-04	Composés pyridazinone

Publications (1)

Publication Number	Publication Date
TN2011000362A1 true TN2011000362A1 (en)	2013-03-27

Family

ID=42398214

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000362A TN2011000362A1 (en)	2009-02-05	2011-07-22	Pyridazinone compounds

Country Status (37)

Country	Link
US (7)	US8354411B2 (fr)
EP (2)	EP3006031A1 (fr)
JP (1)	JP5659166B2 (fr)
KR (1)	KR101730665B1 (fr)
CN (1)	CN102365020B (fr)
AR (1)	AR075238A1 (fr)
AU (1)	AU2010211050B2 (fr)
BR (1)	BRPI1008498B8 (fr)
CA (1)	CA2751565C (fr)
CO (1)	CO6410258A2 (fr)
CR (1)	CR20110440A (fr)
DK (1)	DK2393360T3 (fr)
DO (1)	DOP2011000254A (fr)
EA (1)	EA020690B1 (fr)
EC (1)	ECSP11011305A (fr)
ES (1)	ES2561181T3 (fr)
GE (1)	GEP20146004B (fr)
HR (1)	HRP20160065T1 (fr)
HU (1)	HUE027478T2 (fr)
IL (1)	IL214137A (fr)
JO (1)	JO3114B1 (fr)
MA (1)	MA33072B1 (fr)
ME (1)	ME02337B (fr)
MX (1)	MX2011008305A (fr)
MY (1)	MY170610A (fr)
NZ (1)	NZ594851A (fr)
PE (1)	PE20110991A1 (fr)
PL (1)	PL2393360T3 (fr)
RS (1)	RS54504B1 (fr)
SG (1)	SG173175A1 (fr)
SI (1)	SI2393360T1 (fr)
SM (1)	SMT201600008B (fr)
TN (1)	TN2011000362A1 (fr)
TW (1)	TWI457333B (fr)
UY (1)	UY32417A (fr)
WO (1)	WO2010090737A1 (fr)
ZA (1)	ZA201106074B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009054791A1 (fr) *	2007-10-26	2009-04-30	Astrazeneca Ab	Dérivés de 1,2,4-triazole pyrrolidine fusionnés utilisés en tant que modulateurs de mglur5
CN102099036B (zh)	2008-06-03	2015-05-27	英特芒尼公司	用于治疗炎性疾患和纤维化疾患的化合物和方法
PL2393360T3 (pl)	2009-02-05	2016-04-29	Takeda Pharmaceuticals Co	Związki pirydazynonowe
EA022705B1 (ru)	2010-06-24	2016-02-29	Такеда Фармасьютикал Компани Лимитед	Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
WO2012009194A1 (fr) *	2010-07-12	2012-01-19	Merck Sharp & Dohme Corp.	Inhibiteurs de la tyrosine kinase
EP2601192B1 (fr)	2010-08-04	2017-03-01	Takeda Pharmaceutical Company Limited	Composés hétérocycliques condensés
JP5800813B2 (ja)	2010-08-04	2015-10-28	武田薬品工業株式会社	複素環化合物
WO2012018058A1 (fr)	2010-08-04	2012-02-09	武田薬品工業株式会社	Composé à cycle hétérocyclique fusionné
EP2604597B1 (fr) *	2010-08-10	2017-01-04	Takeda Pharmaceutical Company Limited	Composé hétérocyclique et utilisation de celui-ci comme inhibiteur de phosphodiesterase 10a
JP2013234123A (ja) *	2010-09-03	2013-11-21	Taisho Pharmaceutical Co Ltd	３−ピラゾリル−２−ピリドン誘導体
CA2827724A1 (fr)	2011-02-18	2012-08-23	Allergan, Inc.	Derives de 6,7-dialkoxy-3-isoquinolinol substitues en tant qu'inhibiteurs de la phosphodiesterase 10 (pde10a)
EP2687529B1 (fr)	2011-03-16	2016-07-13	Takeda Pharmaceutical Company Limited	Composé hétérocyclique condensé
US10813630B2 (en)	2011-08-09	2020-10-27	Corquest Medical, Inc.	Closure system for atrial wall
US10307167B2 (en)	2012-12-14	2019-06-04	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
US10314594B2 (en)	2012-12-14	2019-06-11	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
EP2748158B1 (fr)	2011-08-22	2018-01-24	Takeda Pharmaceutical Company Limited	Composés radiomarqués et leur utilisation en tant que radiotraceurs pour l'imagerie quantitative de la phosphodiestérase (pde10a) chez les mammifères
JO3115B1 (ar)	2011-08-22	2017-09-20	Takeda Pharmaceuticals Co	مركبات بيريدازينون واستخدامها كمثبطات daao
US9212147B2 (en)	2011-11-15	2015-12-15	Takeda Pharmaceutical Company Limited	Dihydroxy aromatic heterocyclic compound
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
WO2014071044A1 (fr)	2012-11-01	2014-05-08	Allergan, Inc.	Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
US20140142689A1 (en)	2012-11-21	2014-05-22	Didier De Canniere	Device and method of treating heart valve malfunction
PE20151334A1 (es) *	2013-02-21	2015-10-14	Takeda Pharmaceutical	Metodo de produccion de compuestos de piridazinona
EP2975037A4 (fr)	2013-03-15	2016-08-10	Daiichi Sankyo Co Ltd	Dérivé du benzothiophène
US10039764B2 (en)	2013-07-12	2018-08-07	University Of South Alabama	Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
MX370085B (es) *	2013-09-12	2019-11-29	Janssen Biopharma Inc	Compuestos de piridazinona y usos de los mismos.
WO2015038655A1 (fr)	2013-09-12	2015-03-19	Alios Biopharma, Inc.	Composés d'aza-pyridone et leurs utilisations
US9566443B2 (en)	2013-11-26	2017-02-14	Corquest Medical, Inc.	System for treating heart valve malfunction including mitral regurgitation
US9200016B2 (en)	2013-12-05	2015-12-01	Allergan, Inc.	Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2544869B2 (es) *	2014-03-04	2016-01-18	Universidade De Vigo	Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
WO2015141662A1 (fr)	2014-03-18	2015-09-24	武田薬品工業株式会社	Dispersion solide
JP6525437B2 (ja)	2014-04-02	2019-06-05	インターミューン，インコーポレイテッド	抗線維性ピリジノン
US10842626B2 (en)	2014-12-09	2020-11-24	Didier De Canniere	Intracardiac device to correct mitral regurgitation
CN107531717B (zh)	2015-03-11	2021-07-27	詹森生物制药有限公司	氮杂-吡啶酮化合物及其用途
WO2016191935A1 (fr) *	2015-05-29	2016-12-08	Merck Sharp & Dohme Corp.	Composés 6-alkyle dihydropyrazolopyrimidinone utilisés en tant qu'inhibiteurs de pde2
JP2019503346A (ja)	2015-12-22	2019-02-07	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	ベンゾピペリジン誘導体、その製造方法及びその医薬用途
WO2019161179A1 (fr)	2018-02-15	2019-08-22	Ovid Therapeutics Inc.	Procédés de traitement de syndromes de développement avec des inhibiteurs de pde10a
CN108498868B (zh) *	2018-04-03	2020-09-15	北京大学口腔医学院	具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
CN110407806B (zh) *	2018-04-28	2021-08-17	深圳微芯生物科技股份有限公司	甲酰胺类化合物、其制备方法及其应用
WO2019241787A1 (fr) *	2018-06-15	2019-12-19	The Regents Of The University Of Colorado A Body Corporate	Nouveaux inhibiteurs cycliques de la gmp-amp synthase (cgaz) et leur procédé d'utilisation
EP3856185A1 (fr) *	2018-09-28	2021-08-04	Takeda Pharmaceutical Company Limited	Balipodect pour traiter ou prévenir des troubles du spectre autistique
MX2019008440A (es)	2019-07-15	2021-01-18	Dva Farma Mexicana S A De C V	Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion.
GB202002926D0 (en)	2020-02-28	2020-04-15	Benevolentai Tech Limited	Compositions and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0011693A1 (fr)	1978-10-03	1980-06-11	Ciba-Geigy Ag	N-hétérocycles N-substitués par trifluorométhane-sulfonylaminophényle, leur préparation, compositions les contenant et leur utilisation pour la régulation de la croissance des plantes
FR2648135B1 (fr) *	1989-06-07	1991-09-27	Pf Medicament	Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique
GB9506382D0 (en) *	1995-03-29	1995-05-17	Boots Co Plc	Pharmaceutical compositions
EP1130015A4 (fr)	1998-08-14	2006-02-08	Nihon Nohyaku Co Ltd	Derives de pyridazinone
US20070060606A1 (en) *	1999-10-07	2007-03-15	Robertson Harold A	Compounds and methods for modulating phosphodiesterase 10A
GB0013383D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
KR20030032035A (ko)	2000-09-15	2003-04-23	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피라졸 화합물
US7005432B2 (en)	2002-05-16	2006-02-28	Hoffman-La Roche Inc.	Substituted imidazol-pyridazine derivatives
BRPI0511854A (pt)	2004-06-07	2008-01-15	Pfizer Prod Inc	inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
EP1769092A4 (fr)	2004-06-29	2008-08-06	Europ Nickel Plc	Lixiviation amelioree de metaux de base
JP4302762B2 (ja)	2005-01-07	2009-07-29	ファイザー・プロダクツ・インク	複素環式芳香族キノリン化合物およびｐｄｅ１０阻害剤としてのその使用
US7763617B2 (en)	2005-03-07	2010-07-27	Kyorin Pharmaceutical Co., Ltd.	Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
WO2008001182A1 (fr)	2006-06-26	2008-01-03	Pfizer Products Inc.	Composés hétéroaryliques tricycliques comme inhibiteurs de pde10
TW200801513A (en)	2006-06-29	2008-01-01	Fermiscan Australia Pty Ltd	Improved process
US20080090834A1 (en)	2006-07-06	2008-04-17	Pfizer Inc	Selective azole pde10a inhibitor compounds
EP2219646A4 (fr)	2007-12-21	2010-12-22	Univ Rochester	Procédé permettant de modifier la durée de vie d'organismes eucaryotes
WO2010000020A1 (fr)	2008-06-30	2010-01-07	Cathrx Ltd	Cathéter
TW201030001A (en)	2008-11-14	2010-08-16	Amgen Inc	Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
TWI396689B (zh)	2008-11-14	2013-05-21	Amgen Inc	作為磷酸二酯酶１０抑制劑之吡衍生物
CA2744489C (fr) *	2008-12-04	2015-06-23	F.Hoffmann-La Roche Ag	Derives de pyridazinone
PL2393360T3 (pl) *	2009-02-05	2016-04-29	Takeda Pharmaceuticals Co	Związki pirydazynonowe
US9187455B2 (en) *	2009-02-23	2015-11-17	Hoffmann-La Roche Inc.	Substituted pyridazines as PDE10A inhibitors
US8415381B2 (en)	2009-07-30	2013-04-09	Novartis Ag	Heteroaryl compounds and their uses
WO2012018058A1 (fr) *	2010-08-04	2012-02-09	武田薬品工業株式会社	Composé à cycle hétérocyclique fusionné
EP2604597B1 (fr) *	2010-08-10	2017-01-04	Takeda Pharmaceutical Company Limited	Composé hétérocyclique et utilisation de celui-ci comme inhibiteur de phosphodiesterase 10a

2010
- 2010-02-04 PL PL10738857T patent/PL2393360T3/pl unknown
- 2010-02-04 KR KR1020117020556A patent/KR101730665B1/ko active Active
- 2010-02-04 US US13/148,172 patent/US8354411B2/en active Active
- 2010-02-04 MY MYPI2011003610A patent/MY170610A/en unknown
- 2010-02-04 EA EA201171004A patent/EA020690B1/ru not_active IP Right Cessation
- 2010-02-04 AR ARP100100304A patent/AR075238A1/es active IP Right Grant
- 2010-02-04 CA CA2751565A patent/CA2751565C/fr active Active
- 2010-02-04 US US12/656,605 patent/US8916566B2/en active Active
- 2010-02-04 AU AU2010211050A patent/AU2010211050B2/en active Active
- 2010-02-04 SI SI201031103T patent/SI2393360T1/sl unknown
- 2010-02-04 JO JOP/2010/0038A patent/JO3114B1/ar active
- 2010-02-04 MA MA34133A patent/MA33072B1/fr unknown
- 2010-02-04 ME MEP-2016-194A patent/ME02337B/fr unknown
- 2010-02-04 WO PCT/US2010/000307 patent/WO2010090737A1/fr not_active Ceased
- 2010-02-04 HU HUE10738857A patent/HUE027478T2/en unknown
- 2010-02-04 UY UY0001032417A patent/UY32417A/es not_active Application Discontinuation
- 2010-02-04 DK DK10738857.1T patent/DK2393360T3/en active
- 2010-02-04 ES ES10738857.1T patent/ES2561181T3/es active Active
- 2010-02-04 TW TW099103286A patent/TWI457333B/zh active
- 2010-02-04 SG SG2011054491A patent/SG173175A1/en unknown
- 2010-02-04 EP EP15192646.6A patent/EP3006031A1/fr not_active Withdrawn
- 2010-02-04 EP EP10738857.1A patent/EP2393360B1/fr active Active
- 2010-02-04 JP JP2011549157A patent/JP5659166B2/ja active Active
- 2010-02-04 BR BRPI1008498A patent/BRPI1008498B8/pt active IP Right Grant
- 2010-02-04 PE PE2011001434A patent/PE20110991A1/es active IP Right Grant
- 2010-02-04 CN CN201080014965.6A patent/CN102365020B/zh active Active
- 2010-02-04 NZ NZ594851A patent/NZ594851A/xx unknown
- 2010-02-04 MX MX2011008305A patent/MX2011008305A/es active IP Right Grant
- 2010-02-04 GE GEAP201012363A patent/GEP20146004B/en unknown
- 2010-02-04 HR HRP20160065TT patent/HRP20160065T1/hr unknown
- 2010-02-04 RS RS20150859A patent/RS54504B1/sr unknown
2011
- 2011-07-18 IL IL214137A patent/IL214137A/en active IP Right Grant
- 2011-07-22 TN TN2011000362A patent/TN2011000362A1/fr unknown
- 2011-08-03 DO DO2011000254A patent/DOP2011000254A/es unknown
- 2011-08-17 CR CR20110440A patent/CR20110440A/es unknown
- 2011-08-18 ZA ZA2011/06074A patent/ZA201106074B/en unknown
- 2011-08-23 CO CO11106877A patent/CO6410258A2/es active IP Right Grant
- 2011-09-05 EC EC2011011305A patent/ECSP11011305A/es unknown
2012
- 2012-07-06 US US13/543,207 patent/US8778944B2/en active Active
- 2012-07-06 US US13/543,296 patent/US8513251B2/en active Active
- 2012-07-06 US US13/543,332 patent/US8435995B2/en active Active
2014
- 2014-10-17 US US14/517,313 patent/US9550756B2/en active Active
2016
- 2016-01-08 SM SM201600008T patent/SMT201600008B/it unknown
- 2016-12-13 US US15/377,149 patent/US20170114044A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2010211050A1 (en)	2011-09-08
IL214137A (en)	2015-07-30
ECSP11011305A (es)	2011-11-30
US20120277204A1 (en)	2012-11-01
CO6410258A2 (es)	2012-03-30
GEP20146004B (en)	2014-01-10
DOP2011000254A (es)	2011-09-30
AU2010211050B2 (en)	2016-05-12
RS54504B1 (sr)	2016-06-30
TW201036958A (en)	2010-10-16
EA201171004A1 (ru)	2012-03-30
JP2012516890A (ja)	2012-07-26
NZ594851A (en)	2013-10-25
EA020690B1 (ru)	2015-01-30
MA33072B1 (fr)	2012-02-01
SI2393360T1 (sl)	2016-02-29
HRP20160065T1 (hr)	2016-02-12
MY170610A (en)	2019-08-20
AR075238A1 (es)	2011-03-16
PL2393360T3 (pl)	2016-04-29
US8513251B2 (en)	2013-08-20
US8354411B2 (en)	2013-01-15
CN102365020A (zh)	2012-02-29
PE20110991A1 (es)	2012-02-06
BRPI1008498A2 (pt)	2015-08-25
HUE027478T2 (en)	2016-09-28
HK1164642A1 (zh)	2012-09-28
US20100197651A1 (en)	2010-08-05
CN102365020B (zh)	2014-07-30
EP3006031A1 (fr)	2016-04-13
US20120028951A1 (en)	2012-02-02
EP2393360A1 (fr)	2011-12-14
US8916566B2 (en)	2014-12-23
US8778944B2 (en)	2014-07-15
US20170114044A1 (en)	2017-04-27
US20150099757A1 (en)	2015-04-09
CA2751565A1 (fr)	2010-08-12
ZA201106074B (en)	2012-10-31
UY32417A (es)	2010-08-31
EP2393360A4 (fr)	2012-08-15
JP5659166B2 (ja)	2015-01-28
CA2751565C (fr)	2017-05-16
KR101730665B1 (ko)	2017-04-26
SG173175A1 (en)	2011-09-29
ME02337B (fr)	2016-06-20
BRPI1008498B1 (pt)	2020-02-11
CR20110440A (es)	2012-02-13
US20120277431A1 (en)	2012-11-01
AU2010211050A2 (en)	2011-10-06
SMT201600008B (it)	2016-02-25
JO3114B1 (ar)	2017-09-20
WO2010090737A1 (fr)	2010-08-12
BRPI1008498B8 (pt)	2021-05-25
DK2393360T3 (en)	2016-02-01
TWI457333B (zh)	2014-10-21
EP2393360B1 (fr)	2015-11-04
ES2561181T3 (es)	2016-02-24
US20120277430A1 (en)	2012-11-01
US8435995B2 (en)	2013-05-07
KR20110120931A (ko)	2011-11-04
IL214137A0 (en)	2011-08-31
MX2011008305A (es)	2012-08-15
US9550756B2 (en)	2017-01-24

Publication	Publication Date	Title
TN2011000362A1 (en)	2013-03-27	Pyridazinone compounds
MX2012015098A (es)	2013-05-28	Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
MX2010009736A (es)	2010-09-30	Compuesto heterociclico.
JO2732B1 (en)	2013-09-15	Organic compounds
MY152972A (en)	2014-12-15	Azabicyclo compound and salt thereof
MX2009004920A (es)	2009-05-21	Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2009012283A (es)	2009-11-25	Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
TNSN07348A1 (en)	2008-12-31	Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
MX361020B (es)	2018-11-26	Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
MX2019010100A (es)	2019-10-15	Compuesto de quinolona.
IN2012DN00770A (fr)	2015-06-26
TNSN08494A1 (en)	2010-04-14	Spirocyclic nitriles as protease inhibitors
MY169179A (en)	2019-02-25	Novel piperidine compound or salt thereof
JO3261B1 (ar)	2018-09-16	مشتق بيريدين أحادي الحلقة
WO2009054439A1 (fr)	2009-04-30	Inhibiteur de la production de pai-1
MX353190B (es)	2018-01-05	Derivados de isoquinolina y naftiridina.
IN2012DN00768A (fr)	2015-06-26
NZ611169A (en)	2014-05-30	Pyrazole compounds having therapeutic effect on multiple myeloma
EP2602254A4 (fr)	2014-01-08	Composé hétérocyclique
PH12018502012B1 (en)	2023-03-22	Griseofulvin compound
MX2009004982A (es)	2009-05-20	Derivados heterociclicos como inhibidores cetp.
MX2009005249A (es)	2009-05-28	Compuestos organicos.
PH12013500443A1 (en)	2017-01-04	Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.
NZ595890A (en)	2013-09-27	Pyrazole compound
UA106741C2 (uk)	2014-10-10	Піридазинони